Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.40 |
| ▸ | CDK1 | P06493 | 5/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.39 |
| ▸ | MGMT | P16455 | 4/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1524259 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL546891 | 0.75 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL101669 | 0.75 | CYP3A4 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL29404312 | 0.75 | CYP3A4 (0.67) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL28996831 | 0.73 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL9351658 | 0.69 | CYP1A2 (0.51) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL17372391 | 0.68 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL29421093 | 0.68 | CYP1A2 (0.52) | CYP1A2CYP3A4CYP2D6CYP2C19HSP90AB1 | |
| SCHEMBL16341910 | 0.67 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19POLA1 | |
| SCHEMBL1665221 | 0.66 | KDR (0.50) | CYP1A2CYP3A4CYP2D6CYP2C19CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11015194-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| EP-1615611-A2 | iRNA CONJUGATES | Alnylam Pharmaceuticals Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1608735-A2 | IRNA CONJUGATES | Alnylam Pharmaceuticals (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1605978-A2 | THERAPEUTIC COMPOSITIONS | Alnylam Pharmaceuticals Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005004794-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP3A4 4431/4885CYP2D6 4585/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | CYP1A2 4588/4885CYP3A4 4528/4885CYP2D6 3512/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP3A4 4883/4885CYP2D6 4865/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP3A4 4431/4885CYP2D6 4585/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | CYP1A2 4881/4885CYP3A4 4883/4885CYP2D6 4865/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | CYP1A2 3847/4885CYP3A4 4431/4885CYP2D6 4585/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CYP1A2 2684/4885CYP3A4 3594/4885CYP2D6 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.